MIRCERA Abstracts Ranked Among the Best at Upcoming European Nephrology Congress

Basel, Switzerland (ots/PRNewswire) - Eight presentations
regarding Roche's new anti-anaemia drug MIRCERA(R) currently awaiting
approval worldwide, will feature strongly at the upcoming European
Renal Association-European Dialysis and Transplant Association
(ERA-EDTA) Congress in Barcelona Spain, June 21st to 24th 2007. Three
MIRCERA abstracts have received the accolade of being among the top
eight best abstracts (out of 1191) accepted by the congress this
year.

In addition, Roche's current anaemia treatment NeoRecormon(R) has
3 poster presentations of data from its ongoing GAIN, IRIDIEM and
ORAMA studies.

Details of the MIRCERA and NeoRecormon results will be available
concurrent with when they are presented at the congress. Please note
all information presented at the annual meeting is embargoed for
media release until one hour after the time of presentation.

Summary of presentations
Author Abstract Title Presentation Date & Time
Type of
Presentation
MIRCERA
Presentations
Mann et al. C.E.R.A. provides stable Oral 09:00 -
haemoglobin (Hb) levels in CKD 10:30
(Awarded best patients on dialysis with and
abstract) without coronary artery disease Sunday,
June
(CAD) or diabetes mellitus (DM) 24
when administered once monthly
Ryckelynck et Once-monthly C.E.R.A. maintains Oral 09:00 -
al. stable haemoglobin 10:30
concentrations in dialysis
(Awarded best patients regardless of gender Sunday,
June
abstract) or age 24
Walker et al. C.E.R.A. corrects anaemia and Oral 09:00 -
maintains stable haemoglobin 10:30
(Awarded best (Hb) levels at extended
abstract) administration intervals in a Sunday,
June
52-week study of patients with 24
chronic kidney disease (CKD)
not on dialysis
Imbasciati et Stable haemoglobin (Hb) levels Oral 09:00 -
al. are maintained with 10:30
once-monthly C.E.R.A. in
dialysis patients with varying Sunday,
June
C-reactive protein (CRP), 24
albumin or dialysis adequacy
Chanu et al. Pharmacokinetic parameters of Poster
C.E.R.A. are not affected by
age in patients with chronic 10.30 to
kidney disease on dialysis 12.00 hrs
Saturday,
June 23
Chanu et al. Pharmacokinetics of C.E.R.A. Poster 10.30 to
and stable maintenance of 12.00 hrs
haemoglobin (Hb) levels with
once-monthly dosing in Saturday,
patients with chronic kidney June 23
disease (CKD)
Locatelli et al. The effect of iron status on Poster 10.30 to
haemoglobin (Hb) stability in 12.00 hrs
patients with chronic kidney
disease (CKD) treated with Saturday,
once-monthly C.E.R.A. June 23
Saueressig et Staff time and costs for Poster 10.30 to
al. anaemia management with 12.00 hrs
erythropoietic stimulating
agents in patients on Saturday,
haemodialysis June 23
NeoRecormon
Presentations
Wanner et al. The IRIDIEM survey: CVD Poster 10.30 to
parameters in patients with 12.00 hrs
chronic kidney disease and type
2 diabetes are consistently Friday,
June
under target 22
Locatelli et al. Do guideline-based computer Poster 10.30 to
prompts improve clinical 12.00 hrs
practice in dialysis patients?
- preliminary results of ORAMA Saturday,
study June 23
Rath et al. Hb management in GAIN: dose Poster 10.30 to
saving and administration 12.00 hrs
frequency - final results
Saturday,
June 23

Interested journalists may view the meeting schedule online at
http://www.eraedta2007.org.

ots Originaltext: Roche Pharmaceuticals
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For more information, please contact: Sheila Gies at Roche, Tel:
+973-235-4347, Mobile: +973-687-0188, Diane Lorton at Galliard
Healthcare, Tel: +44-(0)207663-2265, Mobile: +44-(0)7811-358-698